{"id":"W3007141125","doi":"10.1158/1538-7445.sabcs19-ot1-08-08","title":"Abstract OT1-08-08: CONTESSA TRIO: A multinational, multicenter, phase 2 study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with HER2- metastatic breast cancer (MBC)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Atezolizumab; Pembrolizumab; Tolerability; Internal medicine; Taxane; Oncology; Metastatic breast cancer; Cohort; Triple-negative breast cancer; Breast cancer; Chemotherapy; Clinical endpoint; Cancer; Clinical trial; Adverse effect; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002146491,0.0016268,0.001547266,0.0004527893,0.00054149,0.001037751,0.001014452,0.001572415,0.00551762],"category_scores_gemma":[0.00101316,0.0005627174,0.001462325,0.0004600837,0.001069529,0.001121303,0.0004672018,0.003164676,0.00122791],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009185843,"about_ca_system_score_gemma":0.002113634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001783968,"about_ca_topic_score_gemma":0.004289314,"domain_scores_codex":[0.9995745,0.0002120749,0.00001748678,0.00007565429,0.00003761234,0.00008258257],"domain_scores_gemma":[0.998821,0.0001638984,0.0002157677,0.00007021144,0.00007817123,0.0006509044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8432051,0.06479063,0.009426379,0.0006076595,0.001151202,0.0002398378,0.0002709054,0.001548894,0.02580636,0.0003192778,0.008199603,0.04443417],"study_design_scores_gemma":[0.6962416,0.2874056,0.01062998,0.00003715009,0.0004122499,0.0001992434,0.0000522268,0.0009380169,0.00165743,0.0001344346,0.002258389,0.00003369444],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988991,0.001579188,0.0003370243,0.0008967469,0.0001546201,0.003110307,0.002259245,0.000121717,0.002550161],"genre_scores_gemma":[0.976281,0.001847977,0.00219365,0.001892935,0.0004352369,0.004229915,0.006755835,0.00007685391,0.006286468],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00551762,"threshold_uncertainty_score":0.01845831,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05992016180778357,"score_gpt":0.4032915237528517,"score_spread":0.3433713619450681,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}